Through the combination of network pharmacology and in vivo and in vitro experiments, this study found that Gomisin B in YGS may target Toll-like receptor 4 (TLR4), and sensitize CRC stem cells via the NF-κB signaling pathway, inhibit tumor immune escape, and suppress the EMT process. Here, NFKB1 is linked to neoplasm.